Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Oxaliplatin in Pediatric Colon Cancer
NCT02062749Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2014
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin in colon carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of Oxaliplatin at 3 months. Started May 2014; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colon carcinoma
Beyond the preview
Go deeper on NCT02062749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062749.